Practical use of Direct Oral Anti Coagulants (DOACs) in the older persons with atrial fibrillation.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 31740104.
- Also identified by DOI 10.1016/j.ejim.2019.10.026.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Direct Oral Anticoagulants (DOACs) consistently demonstrated a greater net clinical benefit compared to Vitamin K Antagonists (VKAs) also in persons aged 75 years and over, who account for the largest proportion of AF patients; however, major uncertainties in DOACs prescription have to do with this age group. In this review, persistent uncertainties and implications of frailty and geriatric syndromes on DOACs prescription, and practical use of DOACs in real-world older persons, and will be discussed.